-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on DiaMedica Therapeutics, Raises Price Target to $10

Benzinga·03/19/2025 10:45:25
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and raises the price target from $7 to $10.